First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer von Horn, Leora, Mansfield, Aaron S, Szczęsna, Aleksandra, Havel, Libor, Krzakowski, Maciej, Hochmair, Maximilian J, Huemer, Florian, Losonczy, György, Johnson, Melissa L, Nishio, Makoto, Reck, Martin, Mok, Tony, Lam, Sivuonthanh, Shames, David S, Liu, Juan, Ding, Beiying, Lopez-Chavez, Ariel, Kabbinavar, Fairooz, Lin, Wei, Sandler, Alan, Liu, Stephen V

Volltext

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung von Spigel, David R, Edelman, Martin J, O'Byrne, Kenneth, Paz-Ares, Luis, Mocci, Simonetta, Phan, See, Shames, David S, Smith, Dustin, Yu, Wei, Paton, Virginia E, Mok, Tony

Volltext

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer von Patil, Namrata S., Nabet, Barzin Y., Müller, Sören, Koeppen, Hartmut, Zou, Wei, Giltnane, Jennifer, Au-Yeung, Amelia, Srivats, Shyam, Cheng, Jason H., Takahashi, Chikara, de Almeida, Patricia E., Chitre, Avantika S., Grogan, Jane L., Rangell, Linda, Jayakar, Sangeeta, Peterson, Maureen, Hsia, Allison W., O’Gorman, William E., Ballinger, Marcus, Banchereau, Romain, Shames, David S.

Volltext

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab von Gandara, David R., Paul, Sarah M., Kowanetz, Marcin, Schleifman, Erica, Zou, Wei, Li, Yan, Rittmeyer, Achim, Fehrenbacher, Louis, Otto, Geoff, Malboeuf, Christine, Lieber, Daniel S., Lipson, Doron, Silterra, Jacob, Amler, Lukas, Riehl, Todd, Cummings, Craig A., Hegde, Priti S., Sandler, Alan, Ballinger, Marcus, Fabrizio, David, Mok, Tony, Shames, David S.

Volltext

Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers von Goldstein, Leonard D., Lee, James, Gnad, Florian, Klijn, Christiaan, Schaub, Annalisa, Reeder, Jens, Daemen, Anneleen, Bakalarski, Corey E., Holcomb, Thomas, Shames, David S., Hartmaier, Ryan J., Chmielecki, Juliann, Seshagiri, Somasekar, Gentleman, Robert, Stokoe, David

Volltext

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma von Powles, Thomas, Assaf, Zoe June, Davarpanah, Nicole, Banchereau, Romain, Szabados, Bernadett E., Yuen, Kobe C., Grivas, Petros, Hussain, Maha, Oudard, Stephane, Gschwend, Jürgen E., Albers, Peter, Castellano, Daniel, Nishiyama, Hiroyuki, Daneshmand, Siamak, Sharma, Shruti, Zimmermann, Bernhard G., Sethi, Himanshu, Aleshin, Alexey, Perdicchio, Maurizio, Zhang, Jingbin, Shames, David S., Degaonkar, Viraj, Shen, Xiaodong, Carter, Corey, Bais, Carlos, Bellmunt, Joaquim, Mariathasan, Sanjeev

Volltext

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial von Chaft, Jamie E., Oezkan, Filiz, Kris, Mark G., Bunn, Paul A., Wistuba, Ignacio I., Kwiatkowski, David J., Owen, Dwight H., Tang, Yan, Johnson, Bruce E., Lee, Jay M., Lozanski, Gerard, Pietrzak, Maciej, Seweryn, Michal, Byun, Woo Yul, Schulze, Katja, Nicholas, Alan, Johnson, Ann, Grindheim, Jessica, Hilz, Stephanie, Shames, David S., Rivard, Chris, Toloza, Eric, Haura, Eric B., McNamee, Ciaran J., Patterson, G. Alexander, Waqar, Saiama N., Rusch, Valerie W., Carbone, David P.

Volltext

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities von Gay, Carl M., Stewart, C. Allison, Park, Elizabeth M., Diao, Lixia, Groves, Sarah M., Heeke, Simon, Nabet, Barzin Y., Fujimoto, Junya, Solis, Luisa M., Lu, Wei, Xi, Yuanxin, Cardnell, Robert J., Wang, Qi, Fabbri, Giulia, Cargill, Kasey R., Vokes, Natalie I., Ramkumar, Kavya, Zhang, Bingnan, Della Corte, Carminia M., Robson, Paul, Swisher, Stephen G., Roth, Jack A., Glisson, Bonnie S., Shames, David S., Wistuba, Ignacio I., Wang, Jing, Quaranta, Vito, Minna, John, Heymach, John V., Byers, Lauren Averett

Volltext

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial von Peters, Solange, Dziadziuszko, Rafal, Morabito, Alessandro, Felip, Enriqueta, Gadgeel, Shirish M., Cheema, Parneet, Cobo, Manuel, Andric, Zoran, Barrios, Carlos H., Yamaguchi, Masafumi, Dansin, Eric, Danchaivijitr, Pongwut, Johnson, Melissa, Novello, Silvia, Mathisen, Michael S., Shagan, Sarah M., Schleifman, Erica, Wang, Jin, Yan, Mark, Mocci, Simonetta, Voong, David, Fabrizio, David A., Shames, David S., Riehl, Todd, Gandara, David R., Mok, Tony

Volltext

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and... von Mok, Tony, Wu, Yi-Long, Lee, Jin Soo, Yu, Chong-Jen, Sriuranpong, Virote, Sandoval-Tan, Jennifer, Ladrera, Guia, Thongprasert, Sumitra, Srimuninnimit, Vichien, Liao, Meilin, Zhu, Yunzhong, Zhou, Caicun, Fuerte, Fatima, Margono, Benjamin, Wen, Wei, Tsai, Julie, Truman, Matt, Klughammer, Barbara, Shames, David S, Wu, Lin

Volltext

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells von Soh, Junichi, Okumura, Naoki, Lockwood, William W, Yamamoto, Hiromasa, Shigematsu, Hisayuki, Zhang, Wei, Chari, Raj, Shames, David S, Tang, Ximing, MacAulay, Calum, Varella-Garcia, Marileila, Vooder, Tõnu, Wistuba, Ignacio I, Lam, Stephen, Brekken, Rolf, Toyooka, Shinichi, Minna, John D, Lam, Wan L, Gazdar, Adi F

Volltext

Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells von Chen, Pei-Hsuan, Cai, Ling, Huffman, Kenneth, Yang, Chendong, Kim, Jiyeon, Faubert, Brandon, Boroughs, Lindsey, Ko, Bookyung, Sudderth, Jessica, McMillan, Elizabeth A., Girard, Luc, Chen, Dong, Peyton, Michael, Shields, Misty D., Yao, Bo, Shames, David S., Kim, Hyun Seok, Timmons, Brenda, Sekine, Ikuo, Britt, Rebecca, Weber, Stephanie, Byers, Lauren A., Heymach, John V., Chen, Jing, White, Michael A., Minna, John D., Xiao, Guanghua, DeBerardinis, Ralph J.

Volltext

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer von Rudin, Charles M, Durinck, Steffen, Stawiski, Eric W, Poirier, John T, Modrusan, Zora, Shames, David S, Bergbower, Emily A, Guan, Yinghui, Shin, James, Guillory, Joseph, Rivers, Celina Sanchez, Foo, Catherine K, Bhatt, Deepali, Stinson, Jeremy, Gnad, Florian, Haverty, Peter M, Gentleman, Robert, Chaudhuri, Subhra, Janakiraman, Vasantharajan, Jaiswal, Bijay S, Parikh, Chaitali, Yuan, Wenlin, Zhang, Zemin, Koeppen, Hartmut, Wu, Thomas D, Stern, Howard M, Yauch, Robert L, Huffman, Kenneth E, Paskulin, Diego D, Illei, Peter B, Varella-Garcia, Marileila, Gazdar, Adi F, de Sauvage, Frederic J, Bourgon, Richard, Minna, John D, Brock, Malcolm V, Seshagiri, Somasekar

Volltext

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial von Kim, Edward S., Velcheti, Vamsidhar, Mekhail, Tarek, Yun, Cindy, Shagan, Sarah M., Hu, Sylvia, Chae, Young Kwang, Leal, Ticiana A., Dowell, Jonathan E., Tsai, Michaela L., Dakhil, Christopher S. R., Stella, Philip, Jin, Yanling, Shames, David S., Schleifman, Erica, Fabrizio, David A., Phan, See, Socinski, Mark A.

Volltext

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1) von Kowanetz, Marcin, Zou, Wei, Gettinger, Scott N., Koeppen, Hartmut, Kockx, Mark, Schmid, Peter, Kadel, Edward E., Wistuba, Ignacio, Chaft, Jamie, Rizvi, Naiyer A., Spigel, David R., Spira, Alexander, Hirsch, Fred R., Cohen, Victor, Smith, Dustin, Boyd, Zach, Miley, Natasha, Flynn, Susan, Leveque, Vincent, Shames, David S., Ballinger, Marcus, Mocci, Simonetta, Shankar, Geetha, Funke, Roel, Hampton, Garret, Sandler, Alan, Amler, Lukas, Mellman, Ira, Chen, Daniel S., Hegde, Priti S.

Volltext

Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade von Nabet, Barzin Y., Hamidi, Habib, Lee, Myung Chang, Banchereau, Romain, Morris, Stefanie, Adler, Leah, Gayevskiy, Velimir, Elhossiny, Ahmed M., Srivastava, Minu K., Patil, Namrata S., Smith, Kiandra A., Jesudason, Rajiv, Chan, Caleb, Chang, Patrick S., Fernandez, Matthew, Rost, Sandra, McGinnis, Lisa M., Koeppen, Hartmut, Gay, Carl M., Minna, John D., Heymach, John V., Chan, Joseph M., Rudin, Charles M., Byers, Lauren A., Liu, Stephen V., Reck, Martin, Shames, David S.

Volltext

The evolving genomic classification of lung cancer von Shames, David S, Wistuba, Ignacio I

Volltext

Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers von Wilson, Timothy R., Lee, Diana Y., Berry, Leanne, Shames, David S., Settleman, Jeff

Volltext

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer von Assaf, Zoe June F., Zou, Wei, Fine, Alexander D., Socinski, Mark A., Young, Amanda, Lipson, Doron, Freidin, Jonathan F., Kennedy, Mark, Polisecki, Eliana, Nishio, Makoto, Fabrizio, David, Oxnard, Geoffrey R., Cummings, Craig, Rode, Anja, Reck, Martin, Patil, Namrata S., Lee, Mark, Shames, David S., Schulze, Katja

Volltext

Analytical evaluation of circulating tumor DNA sequencing assays von Li, Wenjin, Huang, Xiayu, Patel, Rajesh, Schleifman, Erica, Fu, Shijing, Shames, David S., Zhang, Jingyu

Volltext